GRAIL is a company within the Biotechnology category. GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. They specialize in multi-cancer early detection (MCED) through liquid biopsy technology, specifically using high-intensity sequencing and data science to identify tumor-derived cell-free DNA in the blood.
GRAIL was founded in 2016 and is headquartered in Menlo Park, CA.
GRAIL is rated Contender on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for GRAIL is Strong. Significant factual deltas detected.
AI models classify GRAIL as a Challenger. AI names competitors first.
GRAIL appeared in 6 of 8 sampled buyer-intent queries (75%). GRAIL dominates queries related to 'multi-cancer blood test,' but faces heavy competition for broader 'liquid biopsy' or 'early cancer detection' terms where diagnostic giants are more established.
GRAIL is perceived as a high-innovation leader in the liquid biopsy space. While its technology is highly regarded, the narrative is often crowded by the complex corporate and legal history involving its parent company. Key gap: The most likely discrepancy involves the current corporate ownership and legal status following the European Commission and FTC rulings regarding Illumina's acquisition.
Of 5 key facts verified about GRAIL, 4 are well-documented (likely accurate across AI models), 1 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
The exact regulatory approval status (FDA vs. LDT) and current parent-company relationship are the most volatile data points.
Buyers turn to GRAIL for Wait-and-watch approach: Waiting for symptoms to appear before seeking diagnostic testing., Genetic Risk Assessment Agencies: Using specialized genetic counseling firms to assess hereditary risk rather than active cancer presence., among 2 documented problem areas.
Buyers evaluating GRAIL typically ask AI models about "multi-cancer early detection blood test", "how to get the Galleri test", "total body cancer screening affordable", and 3 similar queries.
GRAIL's main competitors are Guardant Health. According to AI models, these are the brands most frequently named alongside GRAIL in buyer-intent queries.
GRAIL's core products are Galleri multi-cancer early detection test; diagnostic solutions for pharmaceutical companies..
GRAIL uses One-time purchase (typically out-of-pocket/employer-sponsored).
GRAIL serves Healthcare providers, self-insured employers, and individuals over age 50 or at high risk for cancer..
GRAIL The ability to detect signals for over 50 types of cancer with a single blood draw and a very low false-positive rate.
Brand Authority Index (BAI) tier: Contender (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/illumina-grail
Last analyzed: April 10, 2026
Founded: 2016
Headquarters: Menlo Park, California